Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724503 · ClinicalTrials.gov registry record · NA
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
A NA study, sponsored by Sirtex Medical.
- Completed
- Registry status
- NA
- Development phase
- 530
- Enrollment target
NCT00724503 is a NA study that has completed, run by Sirtex Medical. The registered enrollment target is 530 participants.
The verdict
NCT00724503, a NA study, has completed, sponsored by Sirtex Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 530 participants
- Enrollment target
Study Summary
This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy in patients with non-resectable liver metastases from primary colorectal adenocarcinoma. Treatment with the biologic agent bevacizumab, if part of the standard of care at participating institutions, is allowed within this study at the discretion of the treating Investigator.
Interventions
- DEVICE SIR-Spheres yttrium-90 microspheres
- DRUG Systemic chemotherapy (FOLFOX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2006-08 |
| Est. Completion | 2015-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724503
The ClinicalTrials.gov registry entry for NCT00724503 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirtex Medical, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SIR-Spheres yttrium-90 microspheres is the first listed.
NCT00724503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724503 about?
NCT00724503 is a clinical study titled "FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer". This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy in patients with non-resectable liver metastases from primary colorecta...
What is the current status of trial NCT00724503?
This trial is currently completed. It is a NA study. The enrollment target is 530 participants. The study started on 2006-08. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00724503?
The interventions under investigation include: SIR-Spheres yttrium-90 microspheres (DEVICE), Systemic chemotherapy (FOLFOX) (DRUG).
Who is sponsoring clinical trial NCT00724503?
This trial is sponsored by Sirtex Medical, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.